Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...
Behcet's syndrome (BS) is a rare disorder of unknown etiology. Also known as Adamantiades-Behcet's syndrome, it is a multisystem complication of the inflammatory system. It is a combination of ...
Elisha Woodfield has lived with a rare, debilitating condition that has left her covered in ulcers and lesions since first ...
Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...
LIVERPOOL, ENGLAND — The British Society for Rheumatology (BSR) and the British Association of Dermatologists (BAD) have joined forces for the first time to develop the first British guidelines for ...
PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
In our Through My Eyes series, we provide a platform for people to share how a particular medical condition has affected their life. By shining a spotlight on the physical and emotional, this series ...
Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results